Triple hormone agonist yields biggest weight loss seen in trials to date

In a phase 2 trial involving 338 adults with BMI ≥30, or 27 to <30 plus ≥1 weight-related condition, once-weekly treatment with the GLP-1/GIP/glucagon agonist retatrutide resulted in substantial weight reduction at 24 and 48 weeks. Those who received the highest dose (12 mg SC weekly) lost an average of 24.2% of their body weight at 48 weeks. The most common adverse reactions were mild to moderate GI events. A phase 3 trial is planned to inform efficacy and safety of retatrutide for the treatment of obesity.